1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow JS207 injection +JS004 injection: new trials by email Literature Review of JS207 injection +JS004 injection trials Research Report on JS207 injection +JS004 injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy JS207 injection +docetaxel, JS207 injection +JS004 injection, JS207 injection - Advanced NSCLC | Phase 2 | Terminated | Shanghai Junshi Bioscience Co., Ltd. | 18 | 2025-07-15 | 2026-09-25 |
Shanghai Junshi Bioscience Co., Ltd. (1)
China (1)